BRCA1 (C21) Antibody | MyBioSource MBS440100 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

MyBioSource

product type :

antibody

product name :

BRCA1 (C21) Antibody

catalog :

MBS440100

quantity :

0.2 mg

price :

240 USD

clonality :

polyclonal

host :

rabbit

conjugate :

nonconjugated

reactivity :

human

application :

western blot, immunohistochemistry, immunoprecipitation

product information

catalog number :

MBS440100

products type :

Antibody

products full name :

BRCA1 (C21) Antibody

products short name :

BRCA1

other names :

BRCA1; Breast cancer type 1 susceptibility protein; breast cancer type 1 susceptibility protein; BRCA1/BRCA2-containing complex, subunit 1; Fanconi anemia, complementation group S; RING finger protein 53; breast and ovarian cancer susceptibility protein 1; breast and ovarian cancer sususceptibility protein 1; protein phosphatase 1, regulatory subunit 53; truncated breast and ovarian cancer susceptibility protein 1; breast cancer 1, early onset; RING finger protein 53

products gene name :

BRCA1

other gene names :

BRCA1; BRCA1; IRIS; PSCP; BRCAI; BRCC1; FANCS; PNCA4; RNF53; BROVCA1; PPP1R53; RNF53

uniprot entry name :

BRCA1_HUMAN

clonality :

Polyclonal

host :

Rabbit

reactivity :

Human

sequence length :

1863

specificity :

Recognizes Human BRCA1

form :

200 ug/ml rabbit polyclonal IgG in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin.

concentration :

0.200 mg/ml

storage stability :

Store this product at 4 degree C, do not freeze. The product is stable for one year from the date of shipment.

tested application :

Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC)

app notes :

Western blotting starting dilution: 1:200.

other info1 :

Origin: BRCA1 (C21) is an affinity purified rabbit polyclonal antibody, raised against a peptide mapping to the carboxy terminus of human BRCA1.

other info2 :

Immunogen: A synthetic peptide mapping to the carboxy terminus of human BRCA1.

products description :

The breast cancer susceptibility gene 1 (BRCA1) gene was isolated in 1994. Mutations of the gene, a tumor suppressor, are associated with an increased risk for breast, ovarian, and prostate cancers. (1) Point mutations in critical domains and frameshift mutations that lead to early termination of protein translation are associated with a 60-80% risk of breast cancer and a 20-40% risk of ovarian cancer in some studies. (2) BRCA1 is highly polymorphic with more than 1,200 distinct documented variants. Approximately 70% of reported variants lead to absence of full-length BRCA1 protein and are suspected to predispose to cancer. (3) BRCA1 contains several functional domains that directly or indirectly interact with a variety of proteins via protein-protein interaction; these include tumor suppressors (BRCA2, p53, Rb and ATM), oncogenes (c-Myc, casein kinase II and E2F), DNA damage repair proteins (RAD50 and RAD51), cell cycle regulators (cyclins and cyclin dependent kinases), transcriptional activators and repressors (RNA polymerase II, RHA, histone deacetylase complex and CtIP), DNA damage-sensing complex and mismatch repair proteins (BRCA1- Associated Surveillance Complex; BASC) and signal transducer and activator of transcription (STAT). BRCA1 plays a significant role in maintaining genomic stability and serves as a tumor suppressor in breast cancer tumorigenesis. (4)

products references :

1. Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, Xu J, Goldberg ID, Jaiswal AK, Rosen EM. BRCA1 Induces Antioxidant Gene Expression and Resistance to Oxidative Stress. Cancer Res. 2004 Nov 1;64(21):7893-7909.2. Brose MS, Volpe P, Paul K, Stopfer JE, Colligon TA, Calzone KA, Weber BL. Characterization of two novel BRCA1 germ-line mutations involving splice donor sites. Genet Test. 2004 Summer;8(2):133-8.3. Szabo CI, Worley T, Monteiro AN. Understanding Germ-Line Mutations in BRCA1. Cancer Biol Ther. 2004 Jun;3(6):515-20. 4. Jhanwar-Uniyal M. BRCA1 in cancer, cell cycle and genomic stability. Front Biosci. 2003 Sep 01;8:s1107-17.

ncbi gi num :

1698399

ncbi acc num :

AAC37594.1

uniprot acc num :

P38398

ncbi mol weight :

202,342 Da

ncbi pathways :

ATF-2 Transcription Factor Network Pathway 138006!!ATM Mediated Phosphorylation Of Repair Proteins Pathway 105865!!ATM Mediated Response To DNA Double-strand Break Pathway 105864!!Androgen Receptor Signaling Pathway 198806!!Aurora A Signaling Pathway 137925!!BARD1 Signaling Events Pathway 137959!!BRCA1-associated Genome Surveillance Complex (BASC) Pathway 413428!!BRCA1-associated Genome Surveillance Complex (BASC) Pathway 890555!!Cell Cycle Pathway 530733!!Coregulation Of Androgen Receptor Activity Pathway 138085

ncbi summary :

This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2009]

size :

0.2 mg

price :

240 USD